The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Massagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
Hsp90 inhibitors as novel cancer chemotherapeutic agents
Neckers, L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02316-x · Cited by 677
Rasey, J. S., Koh, W.-J., Evans, M. L., Peterson, L. M., Lewellen, T. K., Graham, M. M., & Krohn, K. A. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00325-2 · Cited by 562
Solit, D. B., Zheng, F. F., Drobnjak, M., Münster, P. N., Higgins, B., Verbel, D., Heller, G., Tong, W. P., Cordon‐Cardo, C., Agus, D. B., et al. (2002) · PubMed · Cited by 433
Self-citationHer-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer
Signoretti, S. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1918 · Cited by 397
The epidermal growth factor receptor–tyrosine kinase: A promising therapeutic target in solid tumors
Ritter, C. A., & Arteaga, C. L. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50027 · Cited by 311
Solit, D. B., Basso, A. D., Olshen, A. B., Scher, H. I., & Rosen, N. X. (2003) · PubMed · Cited by 307
Self-citationAnido, J., Matar, P., Albanell, J., Guzmán, M., Rojo, F., Arribas, J., Averbuch, S. D., & Baselga, J. M. (2003) · PubMed · Cited by 264
Targeting HER1/EGFR: A molecular approach to cancer therapy
Arteaga, C. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00185-4 · Cited by 251
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik, G., Kijima, T., Ma, P. C., Ghosh, S. K., Lin, J. J., Shapiro, G. I., Schaefer, E., Tibaldi, E. V., Johnson, B. E., & Salgia, R. (2002) · PubMed · Cited by 228
Scher, H. I., Sarkis, A. S., Reuter, V., Cohen, D., Netto, G. J., Petrylak, D. P., LIANES, P., FUKS, Z. Y., Mendelsohn, J. M., & Cordon‐Cardo, C. (1995) · PubMed · Cited by 214
Smith-Jones, P. M., Vallabahajosula, S., Goldsmith, S. J., Navarro, V., Hunter, C. J., Bastidas, D., & Bander, N. H. (2000) · PubMed · Cited by 212
Self-citationCohen, S. J., Ho, L., Ranganathan, S., Abbruzzese, J. L., Alpaugh, R. K., Beard, M., Lewis, N. L., McLaughlin, S., Rogatko, A., Perez-Ruixo, J. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.040 · Cited by 174
Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells
Qiang, Y., Yao, L., Tosato, G., & Rudikoff, S. (2003) · Blood · doi:10.1182/blood-2003-06-2066 · Cited by 148
Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention
Nahta, R., Hortobágyi, G. N., & Esteva, F. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-1-5 · Cited by 135
Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of Erlotinib (Tarceva)
Hidalgo, M. M., & Bloedow, D. C. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70012-8 · Cited by 107
Harris, L. N., Liotcheva, V. B., Broadwater, G., Ramirez, M. J., Maimonis, P. J., Anderson, S., Everett, T., Harpole, D. H., Moore, M. B., Berry, D. A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1698 · Cited by 96
Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer
Khalil, M. Y., Grandis, J. R., & Shin, D. M. (2003) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.3.3.367 · Cited by 92
Zheng, F. F., Kuduk, S. D., Chiosis, G., Münster, P. N., Sepp‐Lorenzino, L., Danishefsky, S. J., & Rosen, N. X. (2000) · PubMed · Cited by 81
Self-citationHER-Targeted Tyrosine-Kinase Inhibitors
Baselga, J. M., & Hammond, L. A. (2002) · Oncology · doi:10.1159/000066198 · Cited by 76
Neckers, L. (2002) · PubMed · Cited by 65
Clinical Experience with Trastuzumab (Herceptin)
Vogel, C. L., & Franco, S. X. (2003) · The Breast Journal · doi:10.1046/j.1524-4741.2003.09602.x · Cited by 65
Perspectives on Anti-HER Monoclonal Antibodies
Ranson, M., & Sliwkowski, M. X. (2002) · Oncology · doi:10.1159/000066203 · Cited by 63
Current issues in the management of acute promyelocytic leukemia
Slack, J. L., & Rusiniak, M. E. (2000) · Annals of Hematology · doi:10.1007/s002770050585 · Cited by 44
Is there a cloud in the silver lining for imatinib?
Paterson, S., Smith, K. D., Holyoake, T. L., & Jørgensen, H. G. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600828 · Cited by 27
A DVANCES IN THE U NDERSTANDING AND M ANAGEMENT OF A CUTE P ROMYELOCYTIC L EUKEMIA
Mandelli, F., Avvisati, G., & Lo‐Coco, F. (2002) · Reviews in Clinical and Experimental Hematology · doi:10.1046/j.1468-0734.2002.00061.x · Cited by 18
Advances in targeted therapy for chronic myeloid leukemia
Yee, K. W. L., & Keating, A. (2003) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.3.3.295 · Cited by 15
Cited by
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule
Orlova, A., Magnusson, M., Eriksson, T. L. J., Nilsson, M., Larsson, B., Höidén-Guthenberg, I., Widström, C., Carlsson, J., Tolmachev, V., Ståhl, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3521 · Cited by 568
Antunes, P., Ginj, M., Zhang, H., Waser, B., Baum, R. P., Reubi, J. C., & Maecke, H. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0317-x · Cited by 393
Molecular Imaging in the Clinical Arena
Jaffer, F. A. (2005) · JAMA · doi:10.1001/jama.293.7.855 · Cited by 369
Prospective of 68Ga-Radiopharmaceutical Development
Velikyan, I. (2014) · Theranostics · doi:10.7150/thno.7447 · Cited by 336
Metadata
- Authors
- Smith-Jones, P. M., Solit, D. B., Akhurst, T., Afroze, F., Rosen, N., & Larson, S. M.
- Venue
- Nature Biotechnology
- Published
- 2004-05-09
- Volume
- 22
- Issue
- 6
- Pages
- 701-706
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2082717401
- Cited by
- 304
- References
- 27
- FWCI
- 21.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.